XERS SEC Filing News — Xeris Biopharma Holdings, Inc.

Latest SEC filings for Xeris Biopharma Holdings, Inc. (XERS) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-14.

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatmen…
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $2.0B
20
Total Filings
0
Bullish Classifications
10
Bearish Classifications
12
Insider Transactions
4
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for XERS currently lean bearish. Of the 20 filing records displayed, 10 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
XERS Filing Activity Snapshot 2026-07-17 — 2026-10-14
Insider Transactions (Form 4)
0 buys vs 10 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$637.0K
KEVIN MCCULLOCH · 2026-09-28
70,000 shares · Form 144
8-K Item Codes Filed
Item 8.01: Other Events
Item codes identify the type of material event disclosed (e.g. 2.02 = earnings results, 5.02 = executive change, 1.01 = material agreement).
Form 144 Notices
3
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for Xeris Biopharma Holdings, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 10 open-market sale and 2 tax withholding. 10 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×10
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Tax withholding ×2
Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.
Form 4 Open-market sale Insider Selling 2026-10-02

XERS insider Pieper Steven (See Remarks) sold 5,000 shares (~$47.0K)

Pieper Steven, listed as See Remarks at Xeris Biopharma Holdings, Inc., reported an open-market sale of 5,000 XERS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 5,000 $9.41 $47.0K
Filing: Form 4 (Insider Transaction) Insider: Pieper Steven (See Remarks) Shares: 5,000 Est. Value: $47.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-02

XERS insider McCulloch Kevin (See Remarks) sold 15,000 shares (~$141.1K)

McCulloch Kevin, listed as See Remarks at Xeris Biopharma Holdings, Inc., reported an open-market sale of 15,000 XERS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 15,000 $9.41 $141.1K
Filing: Form 4 (Insider Transaction) Insider: McCulloch Kevin (See Remarks) Shares: 15,000 Est. Value: $141.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-02

XERS insider Hecht Beth (See Remarks) sold 16,666 shares (~$156.8K)

Hecht Beth, listed as See Remarks at Xeris Biopharma Holdings, Inc., reported an open-market sale of 16,666 XERS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 16,666 $9.41 $156.8K
Filing: Form 4 (Insider Transaction) Insider: Hecht Beth (See Remarks) Shares: 16,666 Est. Value: $156.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-29

XERS insider McCulloch Kevin (See Remarks) sold 25,000 shares (~$250.0K)

McCulloch Kevin, listed as See Remarks at Xeris Biopharma Holdings, Inc., reported an open-market sale of 25,000 XERS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 25,000 $10.00 $250.0K
Filing: Form 4 (Insider Transaction) Insider: McCulloch Kevin (See Remarks) Shares: 25,000 Est. Value: $250.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-01

XERS insider McCulloch Kevin (See Remarks) sold 15,000 shares (~$127.3K)

McCulloch Kevin, listed as See Remarks at Xeris Biopharma Holdings, Inc., reported an open-market sale of 15,000 XERS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 15,000 $8.49 $127.3K
Filing: Form 4 (Insider Transaction) Insider: McCulloch Kevin (See Remarks) Shares: 15,000 Est. Value: $127.3K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-01

XERS insider Hecht Beth (See Remarks) sold 16,666 shares (~$141.4K)

Hecht Beth, listed as See Remarks at Xeris Biopharma Holdings, Inc., reported an open-market sale of 16,666 XERS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 16,666 $8.49 $141.4K
Filing: Form 4 (Insider Transaction) Insider: Hecht Beth (See Remarks) Shares: 16,666 Est. Value: $141.4K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-01

XERS insider Pieper Steven (See Remarks) sold 5,000 shares (~$42.5K)

Pieper Steven, listed as See Remarks at Xeris Biopharma Holdings, Inc., reported an open-market sale of 5,000 XERS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 5,000 $8.50 $42.5K
Filing: Form 4 (Insider Transaction) Insider: Pieper Steven (See Remarks) Shares: 5,000 Est. Value: $42.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-08-21

XERS insider Form 4 filed for equity award, exercise, or tax withholding

Shannon John Patrick Jr (Director, See Remarks) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 36,645 $8.08 $296.1K
Filing: Form 4 (Insider Transaction) Insider: Shannon John Patrick Jr (Director, See Remarks) Shares: 36,645
View on SEC EDGAR → Open Filing Document →
Form 4 Tax withholding Tax / Compensation Filing 2026-08-21

XERS insider Form 4 filed for equity award, exercise, or tax withholding

McCulloch Kevin (See Remarks) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code Nature Shares Price Value
F Tax withholding on vested shares 21,918 $8.08 $177.1K
Filing: Form 4 (Insider Transaction) Insider: McCulloch Kevin (See Remarks) Shares: 21,918
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-12

XERS insider Pieper Steven (See Remarks) sold 5,000 shares (~$42.5K)

Pieper Steven, listed as See Remarks at Xeris Biopharma Holdings, Inc., reported an open-market sale of 5,000 XERS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 5,000 $8.50 $42.5K
Filing: Form 4 (Insider Transaction) Insider: Pieper Steven (See Remarks) Shares: 5,000 Est. Value: $42.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-04

XERS insider McCulloch Kevin (See Remarks) sold 15,000 shares (~$120.2K)

McCulloch Kevin, listed as See Remarks at Xeris Biopharma Holdings, Inc., reported an open-market sale of 15,000 XERS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 15,000 $8.02 $120.2K
Filing: Form 4 (Insider Transaction) Insider: McCulloch Kevin (See Remarks) Shares: 15,000 Est. Value: $120.2K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-04

XERS insider Hecht Beth (See Remarks) sold 16,666 shares (~$133.6K)

Hecht Beth, listed as See Remarks at Xeris Biopharma Holdings, Inc., reported an open-market sale of 16,666 XERS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 16,666 $8.01 $133.6K
Filing: Form 4 (Insider Transaction) Insider: Hecht Beth (See Remarks) Shares: 16,666 Est. Value: $133.6K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Xeris Biopharma Holdings, Inc. has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-01

XERS Form 144 filed for proposed insider sale by BETH HECHT (16,666 shares) ~$159.3K

BETH HECHT filed a Form 144 with the SEC indicating intent to sell XERS (Xeris Biopharma Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: BETH HECHT Shares: 16,666 Est. Value: $159.3K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-28

XERS Form 144 filed for proposed insider sale by KEVIN MCCULLOCH (70,000 shares) ~$637.0K

KEVIN MCCULLOCH filed a Form 144 with the SEC indicating intent to sell XERS (Xeris Biopharma Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: KEVIN MCCULLOCH Shares: 70,000 Est. Value: $637.0K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-12

XERS Form 144 filed for proposed insider sale by STEVEN PIEPER (20,000 shares) ~$167.8K

STEVEN PIEPER filed a Form 144 with the SEC indicating intent to sell XERS (Xeris Biopharma Holdings, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: STEVEN PIEPER Shares: 20,000 Est. Value: $167.8K
View on SEC EDGAR → Open Filing Document →
Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for Xeris Biopharma Holdings, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

The items reported in this period are: Item 8.01: Other Events.

Form 8-K Material Company Update 2026-10-14

XERS filed 8-K — Other Events

Xeris Biopharma Holdings, Inc. filed an 8-K with the SEC. Item 8.01: Other Events. Filing excerpt: xers-20261013 ☐ 0001867096 0001867096 2026-10-13 2026-10-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2026 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40880 87-1082097 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)…

Filing: 8-K (Material Event) Item 8.01: Other Events
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-09

XERS filed 8-K — material company event

Xeris Biopharma Holdings, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-06

XERS filed 8-K — material company event

Xeris Biopharma Holdings, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-17

XERS filed 8-K — material company event

Xeris Biopharma Holdings, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Xeris Biopharma Holdings, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

XERS filed Quarterly Report (10-Q)

Xeris Biopharma Holdings, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Xeris Biopharma Holdings, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on XERS. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — XERS SEC Filings

More Tools for XERS

XERS Full Stock Analysis XERS Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper XERS analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the XERS stock analysis page.

XERS Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer